期刊文献+

不同时间应用阿昔洛韦干预初发性生殖器疱疹豚鼠模型的治疗效果 被引量:2

下载PDF
导出
摘要 目的观察应用不同时间阿昔洛韦干预初发性生殖器疱疹豚鼠模型的治疗效果。方法取健康豚鼠19只,随机分为5组:立即干预组、3 d干预组、7 d干预组、阳性对照组和阴性对照组。进行豚鼠初发性生殖器疱疹造模,然后在不同时间(造模当天、造模后3 d、造模后7 d)应用阿昔洛韦对生殖器疱疹豚鼠模型进行干预治疗,用外阴症状评分和皮损消退时间进行疗效评价。结果立即干预组的豚鼠皮损积分值低于其他三组,消退时间短于其他三组,组间比较有显著性差异(P<0.05)。结论早期应用阿昔洛韦能很好地控制生殖器疱疹皮损的发展和消退。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第21期4218-4219,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献6

  • 1周文泉,桑红,高建平.生殖器疱疹的流行病学和诊治进展[J].中华男科学杂志,2003,9(8):611-614. 被引量:26
  • 2Tran T, Druce JD, Catton MC, et al. Changing epidemiology of genital her- pes simplex virus infection in Melbourne, Australia, between 1950 and2003 [J]. Sex Transm Infect, 2004 ; 80 (4) :277-9.
  • 3陈信生,范瑞强,李红毅,郖国维.抗病毒胶囊治疗初发性生殖器疱疹豚鼠模型实验研究[J].中国中西医结合皮肤性病学杂志,2002,1(1):11-13. 被引量:5
  • 4Kern ER, Glasgow LA, Overall JC, et al. Treatment of experimental her- pes-virus infections with phosphonoformate and some comparisons with phosphonoacetate [J].Agents Chemother, 1978 ; 14:817-23.
  • 5Suligoi B, Dorrucci M, Volpi A, et al. No protective effect of acyclovir on HIV disease progression in a cohort of HSV-2-HIV-infected individuals[J]. Antivir Ther,2002 ;7 (4) :289-91.
  • 6Hwgh JF. Herpesvirus latency and therapy [J]. Antiviral Res, 2006 ; 71 (3) :127-33.

二级参考文献31

  • 1李红毅,范瑞强,池凤好,廖列辉,禤国维.中药抗病毒胶囊对小鼠T淋巴细胞亚群和IL-2影响的实验研究[J].岭南皮肤性病科杂志,2000,7(4):4-5. 被引量:7
  • 2[2]Kern ER, Glasgow LA, Overall JG, et al. Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate [J]. Antimicrob Agents Chemother,1978.14:817-823.
  • 3[1]Sanchez J, Volquez C, Totten PA, et al. The etiology and man agement of genital ulcers in the Dominican Republic and Peru.[J]. Sex Transm Dis, 2002, 29(10) :559-567.
  • 4[3]Suligoi B, Dorrucci M, Volpi A, et al. Prevalence and determi nants of herpes simplex virus type 2 infection in a cohort of HIV positive individuals in Italy [ J]. Sex Transm Dis, 2002, 29 ( 11 ) :665-667.
  • 5[4]Schacker T, Zeh J, Hu H, et al. Changes in plasma human im munodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression [ J]. J Infect Dis, 2002, 186(12): 1718-1725.
  • 6[5]Mihret W, Rinke de Wit TF, Petros B, et al. Herpes simplex vi rus type 2 seropositivity among urban adults in Africa: results from two cross-sectional surveys in Addis Ababa, Ethiopia[ J]. Sex Transm Dis, 2002, 29(3) :175-181.
  • 7[6]Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994 [J]. N Engl J Med, 1997, 337(16) :1105-1111.
  • 8[7]Smith JS, Herrero R, Munoz N, et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines [ J ]. Sex Transm Dis, 2001, 28 (4) :187 ~ 194.
  • 9[8]Laccano-Ponce E, Smith JS, Munoz N, et al. High prevalence of antibodies to herpes simplex virus type 2 among middle-aged women in Mexico City, Mexico: a population-based study [ J ]. Sex Transm Dis, 2001,28 (5) :270-276.
  • 10[9]Patrick DM, Dawar M, Cook DA, et al. Antenatal seroprevalence of herpes simplex virus type 2 ( HSV-2 ) in Canadian women: HSV 2 prevalence increases throughout the reproductive years[ J ]. Sex Transm Dis, 2001, 28 ( 7 ) :424 -428.

共引文献29

同被引文献16

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部